company background image
1877

Shanghai Junshi Biosciences SEHK:1877 Stock Report

Last Price

HK$31.70

Market Cap

HK$54.3b

7D

-2.6%

1Y

-32.4%

Updated

16 Aug, 2022

Data

Company Financials +
1877 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

1877 Stock Overview

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China.

Shanghai Junshi Biosciences Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Junshi Biosciences
Historical stock prices
Current Share PriceHK$31.70
52 Week HighHK$68.65
52 Week LowHK$29.90
Beta0.13
1 Month Change-17.56%
3 Month Change-42.52%
1 Year Change-32.41%
3 Year Change4.45%
5 Year Changen/a
Change since IPO33.47%

Recent News & Updates

Shareholder Returns

1877HK BiotechsHK Market
7D-2.6%0.6%-0.5%
1Y-32.4%-51.2%-20.6%

Return vs Industry: 1877 exceeded the Hong Kong Biotechs industry which returned -51.8% over the past year.

Return vs Market: 1877 underperformed the Hong Kong Market which returned -21.6% over the past year.

Price Volatility

Is 1877's price volatile compared to industry and market?
1877 volatility
1877 Average Weekly Movement9.5%
Biotechs Industry Average Movement7.8%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 1877 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 1877's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
20122,805Ning Lihttps://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection.

Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary

How do Shanghai Junshi Biosciences's earnings and revenue compare to its market cap?
1877 fundamental statistics
Market CapHK$54.30b
Earnings (TTM)-HK$1.73b
Revenue (TTM)HK$3.52b

8.2x

P/S Ratio

-16.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1877 income statement (TTM)
RevenueCN¥3.04b
Cost of RevenueCN¥1.14b
Gross ProfitCN¥1.90b
Other ExpensesCN¥3.39b
Earnings-CN¥1.49b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.64
Gross Margin62.41%
Net Profit Margin-49.18%
Debt/Equity Ratio6.5%

How did 1877 perform over the long term?

See historical performance and comparison